Biogen and Envisagenics Enter into a Collaboration for the Advancement of RNA Splicing Research to Treat Central Nervous System Diseases
Shots:
- Biogen will utilize Envisagenics’ SpliceCore- an AI- driven RNA splicing platform to understand the regulation of different RNA isoforms in CNS cell types which will provide access to SpliceCore’s database of ~7M RNA splicing errors
- The collaboration will identify and validate disease genetic targets to increase the success rate in the CNS drug discovery
- The addition of Envisagenics’ machine learning algorithms and high-performance computing helps to identify- test- and validate splicing errors at a large scale
Ref: GLOBE NEWSWIRE | Image: Biogen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com